Retinal vascular disease: Think globally

Article

In patients with signs of retinal vascular disease, optometrists must consider the bigger picture. If a patient has hypertension, diabetes, hyperlipidemia or associated retinal changes, optometrists should be asking whether the patient has metabolic syndrome.

"Metabolic syndrome is a complex disorder with rising prevalence that is associated with significantly increased risks of cardiovascular disease and diabetes, but also with microvascular disease, including retinal complications that may put patients at risk for sight-threatening events," said Dr. Joy, Mooresville, NC.

"Therefore, in our everyday busy practices," he continued, "it is increasingly important that optometrists look at patients globally in terms of their overall systemic health and work collaboratively with our colleagues in primary care and retina to ensure that all treatable conditions are addressed and to help patients maintain optimal vision."

"Optometrists are very good at recognizing the individual pathological changes associated with diabetes, hypertension, or hypercholesterolemia. Considering the diagnosis of metabolic syndrome is a different and very important thought process," he said.

Recent Videos
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
Ali Tafreshi sits down with Optometry Times to discuss Topcon's "Healthcare from the Eye" initiative.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
OptiLIFT in action: Dr. Julie McLaughlin's experience with the new device
© 2025 MJH Life Sciences

All rights reserved.